|I. General information|
|Background:||The cell line is derived from an older patient with a germline mutation in the FHIT gene. The FHIT gene is located at 3p14.2 and the mutation is a transversion at nucleotide 651 (G to T).The patient's daughter carries the same gene mutation.
This cell line was initiated on 3/8/95 and took 19 months to establish.
|Species:||Homo sapiens, human|
|Tissue:||mammary gland; breast|
|Disease:||TNM stage IV, grade 3, primary metaplastic carcinoma|
|Gender:||female，70 years， Black|
|Growth Mode:||mixed adherent-suspension|
We strongly suggest to purchase the complete medium from Cobioer.
|Receptor Expression:||estrogen receptor, negative
progesterone receptor, negative
|Oncogene:||her2/neu +, p53 -|
|Genes Expressed:||Epithelial glycoprotein 2 [EGP2]; cytokeratin 19|
|Cellular Products:||Epithelial glycoprotein 2 [EGP2]; cytokeratin 19|
|Comments:||The patient received prior chemotherapy and had no family history of breast cancer. The tumor was classified as TNM stage IV, grade 3, metaplastic carcinoma with 4 out of 18 lymph node metastasis.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu and negative for expression of p53.
HCC1569 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR) by immunohistochemistry, but PR expression was detectable at a low level by cytosolic protein assay.
For more information, please contact Cobioer (4008-750-250).